BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION

巴里将包括一项前瞻性随机试验，旨在比较 PTCA和CABG在冠心病患者临床亚群中的长期疗效 多支冠状动脉疾病和严重心绞痛、不稳定心绞痛或心绞痛 急性心肌梗死后，以及所有接受冠状动脉造影的患者 12岁时因严重或不稳定型心绞痛（伴或不伴MI）进行血管造影 参与临床研究中心。 大约1,800名患者将被随机分配到 24个月招募期内的PTCA或CABG以及 后续行动将至少持续四年。 临床和客观数据 将收集登记研究和随机化研究中每例受试者的 在入组时和随访期间进行试验。 治疗的最佳选择尚不清楚 目前，对于这些患有严重冠状动脉疾病的大部分患者， 疾病和随机试验应建立相对优点， PTCA和CABG，即每种手术的安全性和成功率， 心绞痛复发率、再次干预的需要和晚期 冠状动脉事件，并帮助确定应采用哪种程序 先 登记册数据的若干目标之一是评估 将试验结论扩展到更大人群的有效性 严重心绞痛和多支冠状动脉疾病的患者。

BARI will consist of a prospective randomized trial designed to compare the long-term efficacy of PTCA and CABG in clinical subsets of patients with multivessel coronary disease and severe angina, unstable angina or angina after acute MI, and a registry of all patients undergoing coronary angiography because of severe or unstable angina, with or without MI, at 12 participating clinical sites. Roughly 1,800 patients will be randomized to PTCA or CABG during the 24-month recruitment period and duration of follow-up will be a minimum of four years. Clinical and objective data will be collected for each subject in the registry and in the randomized trial at entry and during follow-up. The best choice of therapy is unclear at present for these large subsets of patients with severe coronary artery disease and the randomized trial should establish the relative merits of PTCA and CABG, namely the safety and rate of success of each procedure, recurrence rate of angina, need for re-intervention and occurrence of late coronary events, and help to determine which procedure should be applied first. The registry data will, among several objectives, assess the validity of extending the conclusions of the trial to a larger population of patients with severe angina and multivessel coronary disease.